Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066542 | 0.86 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL18547184 | 0.86 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL27410776 | 0.83 | CPN1 (0.49) | SLC6A4SLC6A3SLC6A2LMNAMEN1 | |
| SCHEMBL66920 | 0.82 | LMNA (0.54) | CYP2D6SRCLMNAMEN1MAPT | |
| SCHEMBL13114874 | 0.81 | CACNA2D1 (0.50) | SLC6A4SLC6A3SLC6A2LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL11359974 | 0.80 | LMNA (0.53) | CYP2D6SRCLMNAMEN1MAPT | |
| SCHEMBL67619 | 0.78 | HTR1E (0.60) | SLC6A3SLC6A2CYP2D6LMNAMEN1 | |
| SCHEMBL69127 | 0.78 | HTR1E (0.65) | SLC6A3SLC6A2CYP2D6LMNAMEN1 | |
| SCHEMBL28622389 | 0.78 | HTR1E (0.65) | SLC6A3SLC6A2CYP2D6LMNAMEN1 | |
| SCHEMBL17844351 | 0.77 | CYP2D6 (0.43) | SLC6A3CYP2D6SRCLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | SLC6A4 2021/4885SLC6A3 2983/4885SLC6A2 3285/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | SLC6A4 2015/4885SLC6A3 2980/4885SLC6A2 3256/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | SLC6A4 2015/4885SLC6A3 2980/4885SLC6A2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.